Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
University of Florida · University of Alabama at Birmingham · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
63
total citations
- FWCI
- 66.92
- Percentile
- 100%
- References
- 41
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Steatosis
- Insulin resistance
- Type 2 diabetes
- Internal medicine
- Agonist
- Endocrinology
- Pioglitazone
- Medicine
UN Sustainable Development Goals
- Zero hunger
No related works found for this paper.